Renovion Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$15M
- Investors
-
4
Renovion General Information
Description
Developer of an advanced nebulized therapy designed to treat chronic inflammatory airway diseases. The company's therapy develops a drug for patients with bronchiectasis, who have received a bilateral lung transplant, and other mucus-related diseases such as chronic bronchitis and obstructive pulmonary disease, enabling healthcare professionals to address the mucus, inflammation, and infection associated with lung diseases.
Contact Information
Website
www.renovion.comCorporate Office
- 900 Martin Luther King, Junior Boulevard
- Suite A
- Chapel Hill, NC 27514
- United States
Corporate Office
- 900 Martin Luther King, Junior Boulevard
- Suite A
- Chapel Hill, NC 27514
- United States
Renovion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 28-Mar-2023 | $15M | Completed | Clinical Trials - Phase 3 | ||
| 5. Later Stage VC (Series A) | 29-May-2020 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series A3) | 05-Feb-2019 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC | 15-May-2018 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 17-Jan-2017 | $1.87M | $1.92M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 22-Sep-2016 | $50K | $50K | Completed | Pre-Clinical Trials |
Renovion Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 119,454 | $2.93 | $2.93 | 1x | $2.93 | 2.17% | ||
| Series A-1 | 637,862 | $2.93 | $2.93 | 1x | $2.93 | 11.61% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Renovion Comparisons
Industry
Financing
Details
Renovion Competitors (3)
One of Renovion’s 3 competitors is Verona Pharma, a Private Debt Financed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verona Pharma | Private Debt Financed | London, United Kingdom | ||||
| Laurent Pharma | Venture Capital-Backed | Montreal, Canada | ||||
| AN2 Therapeutics | Formerly VC-backed | Menlo Park, CA |
Renovion Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Renovion Patents
Renovion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4460319-A2 | Aqueous solution comprising a glutathione salt | Pending | 04-Jan-2022 | ||
| CA-3240818-A1 | Aqueous solution comprising a glutathione salt | Pending | 04-Jan-2022 | ||
| US-12097238-B2 | Aqueous solution comprising a glutathione salt | Active | 04-Jan-2022 | ||
| US-20240424052-A1 | Aqueous solution comprising a glutathione salt | Pending | 04-Jan-2022 | ||
| AU-2023205178-A1 | Aqueous solution comprising a glutathione salt | Pending | 04-Jan-2022 | A61K9/08 |
Renovion Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Renovion Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Onbelay Capital | Merchant Banking Firm | Minority | ||
| Texas Halo Fund | Venture Capital | Minority | ||
| WhiteRock Capital Partners | Investment Bank | Minority | ||
| First Flight Venture Center | Accelerator/Incubator | Minority |
Renovion FAQs
-
When was Renovion founded?
Renovion was founded in 2013.
-
Where is Renovion headquartered?
Renovion is headquartered in Chapel Hill, NC.
-
What is the size of Renovion?
Renovion has 6 total employees.
-
What industry is Renovion in?
Renovion’s primary industry is Drug Discovery.
-
Is Renovion a private or public company?
Renovion is a Private company.
-
What is Renovion’s current revenue?
The current revenue for Renovion is .
-
How much funding has Renovion raised over time?
Renovion has raised $25.9M.
-
Who are Renovion’s investors?
Onbelay Capital, Texas Halo Fund, WhiteRock Capital Partners, and First Flight Venture Center have invested in Renovion.
-
Who are Renovion’s competitors?
Verona Pharma, Laurent Pharma, and AN2 Therapeutics are competitors of Renovion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
